nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0354	0.0543	CbGbCtD
Paroxetine—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0333	0.051	CbGbCtD
Paroxetine—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0333	0.051	CbGbCtD
Paroxetine—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0301	0.0462	CbGbCtD
Paroxetine—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.0252	0.0387	CbGbCtD
Paroxetine—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.0228	0.035	CbGbCtD
Paroxetine—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0228	0.035	CbGbCtD
Paroxetine—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0228	0.035	CbGbCtD
Paroxetine—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0187	0.0287	CbGbCtD
Paroxetine—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0176	0.027	CbGbCtD
Paroxetine—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0176	0.027	CbGbCtD
Paroxetine—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0173	0.0265	CbGbCtD
Paroxetine—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0173	0.0265	CbGbCtD
Paroxetine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0171	0.0262	CbGbCtD
Paroxetine—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0171	0.0262	CbGbCtD
Paroxetine—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0166	0.0254	CbGbCtD
Paroxetine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0161	0.0247	CbGbCtD
Paroxetine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0161	0.0247	CbGbCtD
Paroxetine—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0159	0.0244	CbGbCtD
Paroxetine—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0159	0.0244	CbGbCtD
Paroxetine—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0154	0.0237	CbGbCtD
Paroxetine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0145	0.0223	CbGbCtD
Paroxetine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0145	0.0223	CbGbCtD
Paroxetine—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0137	0.021	CbGbCtD
Paroxetine—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0133	0.0204	CbGbCtD
Paroxetine—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0133	0.0204	CbGbCtD
Paroxetine—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0129	0.0198	CbGbCtD
Paroxetine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0125	0.0192	CbGbCtD
Paroxetine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0122	0.0187	CbGbCtD
Paroxetine—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.012	0.0185	CbGbCtD
Paroxetine—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.012	0.0185	CbGbCtD
Paroxetine—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0117	0.0179	CbGbCtD
Paroxetine—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0117	0.0179	CbGbCtD
Paroxetine—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0115	0.0177	CbGbCtD
Paroxetine—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0112	0.0172	CbGbCtD
Paroxetine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.011	0.0169	CbGbCtD
Paroxetine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.011	0.0169	CbGbCtD
Paroxetine—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00867	0.0133	CbGbCtD
Paroxetine—TACR1—nerve—acquired immunodeficiency syndrome	0.00426	0.0813	CbGeAlD
Paroxetine—SLC6A3—nerve—acquired immunodeficiency syndrome	0.00214	0.0409	CbGeAlD
Paroxetine—SLC6A2—nerve—acquired immunodeficiency syndrome	0.00173	0.033	CbGeAlD
Paroxetine—SLC6A4—blood plasma—acquired immunodeficiency syndrome	0.00149	0.0283	CbGeAlD
Paroxetine—TACR1—digestive system—acquired immunodeficiency syndrome	0.00124	0.0236	CbGeAlD
Paroxetine—TACR1—blood—acquired immunodeficiency syndrome	0.00118	0.0225	CbGeAlD
Paroxetine—CHRM5—skin of body—acquired immunodeficiency syndrome	0.00114	0.0217	CbGeAlD
Paroxetine—TACR1—spinal cord—acquired immunodeficiency syndrome	0.00114	0.0217	CbGeAlD
Paroxetine—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00107	0.0205	CbGeAlD
Paroxetine—HTR2A—nerve—acquired immunodeficiency syndrome	0.00104	0.0198	CbGeAlD
Paroxetine—TACR1—lung—acquired immunodeficiency syndrome	0.00103	0.0197	CbGeAlD
Paroxetine—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.000963	0.0184	CbGeAlD
Paroxetine—TACR1—nervous system—acquired immunodeficiency syndrome	0.000958	0.0183	CbGeAlD
Paroxetine—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000954	0.0182	CbGeAlD
Paroxetine—TACR1—central nervous system—acquired immunodeficiency syndrome	0.000923	0.0176	CbGeAlD
Paroxetine—CHRM4—nervous system—acquired immunodeficiency syndrome	0.000901	0.0172	CbGeAlD
Paroxetine—HTR2A—endothelium—acquired immunodeficiency syndrome	0.000885	0.0169	CbGeAlD
Paroxetine—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.000867	0.0165	CbGeAlD
Paroxetine—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.000786	0.015	CbGeAlD
Paroxetine—TACR1—brain—acquired immunodeficiency syndrome	0.000732	0.014	CbGeAlD
Paroxetine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000716	0.0137	CbGeAlD
Paroxetine—TACR1—lymph node—acquired immunodeficiency syndrome	0.000708	0.0135	CbGeAlD
Paroxetine—CHRM5—nervous system—acquired immunodeficiency syndrome	0.000704	0.0134	CbGeAlD
Paroxetine—CHRM4—brain—acquired immunodeficiency syndrome	0.000689	0.0131	CbGeAlD
Paroxetine—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.000678	0.0129	CbGeAlD
Paroxetine—SLC6A3—spinal cord—acquired immunodeficiency syndrome	0.000572	0.0109	CbGeAlD
Paroxetine—SLC6A4—digestive system—acquired immunodeficiency syndrome	0.000571	0.0109	CbGeAlD
Paroxetine—SLC6A4—blood—acquired immunodeficiency syndrome	0.000544	0.0104	CbGeAlD
Paroxetine—CHRM5—brain—acquired immunodeficiency syndrome	0.000538	0.0103	CbGeAlD
Paroxetine—SLC6A4—spinal cord—acquired immunodeficiency syndrome	0.000524	0.01	CbGeAlD
Paroxetine—SLC6A3—lung—acquired immunodeficiency syndrome	0.00052	0.00993	CbGeAlD
Paroxetine—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000515	0.00982	CbGeAlD
Paroxetine—CHRM3—digestive system—acquired immunodeficiency syndrome	0.000509	0.00971	CbGeAlD
Paroxetine—CHRM2—nervous system—acquired immunodeficiency syndrome	0.000483	0.00922	CbGeAlD
Paroxetine—SLC6A3—nervous system—acquired immunodeficiency syndrome	0.000482	0.00919	CbGeAlD
Paroxetine—SLC6A4—lung—acquired immunodeficiency syndrome	0.000477	0.0091	CbGeAlD
Paroxetine—CHRM1—lung—acquired immunodeficiency syndrome	0.000475	0.00906	CbGeAlD
Paroxetine—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.000465	0.00888	CbGeAlD
Paroxetine—SLC6A3—central nervous system—acquired immunodeficiency syndrome	0.000464	0.00885	CbGeAlD
Paroxetine—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000463	0.00884	CbGeAlD
Paroxetine—SLC6A4—nervous system—acquired immunodeficiency syndrome	0.000442	0.00843	CbGeAlD
Paroxetine—CHRM1—nervous system—acquired immunodeficiency syndrome	0.00044	0.00839	CbGeAlD
Paroxetine—HTR2A—retina—acquired immunodeficiency syndrome	0.00043	0.00821	CbGeAlD
Paroxetine—SLC6A4—central nervous system—acquired immunodeficiency syndrome	0.000425	0.00811	CbGeAlD
Paroxetine—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.000424	0.00808	CbGeAlD
Paroxetine—SLC6A2—lung—acquired immunodeficiency syndrome	0.00042	0.00801	CbGeAlD
Paroxetine—CHRM3—nervous system—acquired immunodeficiency syndrome	0.000394	0.00751	CbGeAlD
Paroxetine—CYP2C8—blood—acquired immunodeficiency syndrome	0.000393	0.00751	CbGeAlD
Paroxetine—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000389	0.00742	CbGeAlD
Paroxetine—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.000379	0.00723	CbGeAlD
Paroxetine—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000375	0.00716	CbGeAlD
Paroxetine—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000374	0.00714	CbGeAlD
Paroxetine—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.00037	0.00707	CbGeAlD
Paroxetine—CHRM2—brain—acquired immunodeficiency syndrome	0.000369	0.00705	CbGeAlD
Paroxetine—SLC6A3—brain—acquired immunodeficiency syndrome	0.000368	0.00703	CbGeAlD
Paroxetine—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000367	0.007	CbGeAlD
Paroxetine—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000365	0.00696	CbGeAlD
Paroxetine—CYP2B6—blood—acquired immunodeficiency syndrome	0.000353	0.00673	CbGeAlD
Paroxetine—CYP2C9—blood—acquired immunodeficiency syndrome	0.000349	0.00667	CbGeAlD
Paroxetine—SLC6A4—brain—acquired immunodeficiency syndrome	0.000338	0.00644	CbGeAlD
Paroxetine—CHRM1—brain—acquired immunodeficiency syndrome	0.000336	0.00642	CbGeAlD
Paroxetine—CYP2B6—vagina—acquired immunodeficiency syndrome	0.000327	0.00624	CbGeAlD
Paroxetine—CYP2B6—lung—acquired immunodeficiency syndrome	0.000309	0.0059	CbGeAlD
Paroxetine—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000302	0.00576	CbGeAlD
Paroxetine—CHRM3—brain—acquired immunodeficiency syndrome	0.000301	0.00574	CbGeAlD
Paroxetine—SLC6A2—brain—acquired immunodeficiency syndrome	0.000297	0.00567	CbGeAlD
Paroxetine—HTR2A—blood—acquired immunodeficiency syndrome	0.000288	0.00549	CbGeAlD
Paroxetine—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000287	0.00548	CbGeAlD
Paroxetine—CYP2B6—nervous system—acquired immunodeficiency syndrome	0.000287	0.00547	CbGeAlD
Paroxetine—ABCB1—retina—acquired immunodeficiency syndrome	0.000282	0.00538	CbGeAlD
Paroxetine—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000277	0.00529	CbGeAlD
Paroxetine—CYP2B6—central nervous system—acquired immunodeficiency syndrome	0.000276	0.00526	CbGeAlD
Paroxetine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000275	0.00525	CbGeAlD
Paroxetine—HTR2A—vagina—acquired immunodeficiency syndrome	0.000267	0.00509	CbGeAlD
Paroxetine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000262	0.005	CbGeAlD
Paroxetine—HTR2A—lung—acquired immunodeficiency syndrome	0.000252	0.00481	CbGeAlD
Paroxetine—CYP2C8—brain—acquired immunodeficiency syndrome	0.000244	0.00466	CbGeAlD
Paroxetine—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000234	0.00446	CbGeAlD
Paroxetine—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000225	0.00429	CbGeAlD
Paroxetine—CYP2B6—brain—acquired immunodeficiency syndrome	0.000219	0.00418	CbGeAlD
Paroxetine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000213	0.00406	CbGeAlD
Paroxetine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000205	0.00391	CbGeAlD
Paroxetine—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.0002	0.00382	CbGeAlD
Paroxetine—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000198	0.00378	CbGeAlD
Paroxetine—ABCB1—blood—acquired immunodeficiency syndrome	0.000189	0.0036	CbGeAlD
Paroxetine—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000183	0.00348	CbGeAlD
Paroxetine—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000182	0.00347	CbGeAlD
Paroxetine—HTR2A—brain—acquired immunodeficiency syndrome	0.000179	0.00341	CbGeAlD
Paroxetine—ABCB1—vagina—acquired immunodeficiency syndrome	0.000175	0.00334	CbGeAlD
Paroxetine—ABCB1—lung—acquired immunodeficiency syndrome	0.000165	0.00316	CbGeAlD
Paroxetine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000163	0.0031	CbGeAlD
Paroxetine—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000153	0.00292	CbGeAlD
Paroxetine—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000147	0.00281	CbGeAlD
Paroxetine—ABCB1—brain—acquired immunodeficiency syndrome	0.000117	0.00223	CbGeAlD
Paroxetine—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000113	0.00216	CbGeAlD
Paroxetine—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	6.34e-05	0.000242	CcSEcCtD
Paroxetine—Anaemia—Lamivudine—acquired immunodeficiency syndrome	6.34e-05	0.000242	CcSEcCtD
Paroxetine—Anxiety—Ritonavir—acquired immunodeficiency syndrome	6.34e-05	0.000242	CcSEcCtD
Paroxetine—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	6.32e-05	0.000241	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	6.32e-05	0.000241	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	6.3e-05	0.00024	CcSEcCtD
Paroxetine—Pruritus—Abacavir—acquired immunodeficiency syndrome	6.29e-05	0.00024	CcSEcCtD
Paroxetine—Fatigue—Indinavir—acquired immunodeficiency syndrome	6.29e-05	0.00024	CcSEcCtD
Paroxetine—Discomfort—Ritonavir—acquired immunodeficiency syndrome	6.29e-05	0.00024	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	6.28e-05	0.000239	CcSEcCtD
Paroxetine—Cough—Saquinavir—acquired immunodeficiency syndrome	6.28e-05	0.000239	CcSEcCtD
Paroxetine—Angioedema—Lamivudine—acquired immunodeficiency syndrome	6.27e-05	0.000239	CcSEcCtD
Paroxetine—Constipation—Indinavir—acquired immunodeficiency syndrome	6.24e-05	0.000238	CcSEcCtD
Paroxetine—Pain—Indinavir—acquired immunodeficiency syndrome	6.24e-05	0.000238	CcSEcCtD
Paroxetine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	6.24e-05	0.000238	CcSEcCtD
Paroxetine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	6.23e-05	0.000238	CcSEcCtD
Paroxetine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	6.23e-05	0.000238	CcSEcCtD
Paroxetine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	6.22e-05	0.000237	CcSEcCtD
Paroxetine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	6.21e-05	0.000237	CcSEcCtD
Paroxetine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	6.2e-05	0.000236	CcSEcCtD
Paroxetine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	6.2e-05	0.000236	CcSEcCtD
Paroxetine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	6.2e-05	0.000236	CcSEcCtD
Paroxetine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	6.19e-05	0.000236	CcSEcCtD
Paroxetine—Malaise—Lamivudine—acquired immunodeficiency syndrome	6.19e-05	0.000236	CcSEcCtD
Paroxetine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	6.18e-05	0.000235	CcSEcCtD
Paroxetine—Nausea—Didanosine—acquired immunodeficiency syndrome	6.18e-05	0.000235	CcSEcCtD
Paroxetine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	6.17e-05	0.000235	CcSEcCtD
Paroxetine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	6.16e-05	0.000235	CcSEcCtD
Paroxetine—Syncope—Lamivudine—acquired immunodeficiency syndrome	6.15e-05	0.000235	CcSEcCtD
Paroxetine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	6.15e-05	0.000234	CcSEcCtD
Paroxetine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	6.15e-05	0.000234	CcSEcCtD
Paroxetine—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	6.14e-05	0.000234	CcSEcCtD
Paroxetine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	6.13e-05	0.000234	CcSEcCtD
Paroxetine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	6.12e-05	0.000233	CcSEcCtD
Paroxetine—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	6.12e-05	0.000233	CcSEcCtD
Paroxetine—Myalgia—Saquinavir—acquired immunodeficiency syndrome	6.12e-05	0.000233	CcSEcCtD
Paroxetine—Anxiety—Saquinavir—acquired immunodeficiency syndrome	6.1e-05	0.000233	CcSEcCtD
Paroxetine—Oedema—Ritonavir—acquired immunodeficiency syndrome	6.1e-05	0.000233	CcSEcCtD
Paroxetine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	6.08e-05	0.000232	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	6.08e-05	0.000232	CcSEcCtD
Paroxetine—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	6.07e-05	0.000231	CcSEcCtD
Paroxetine—Discomfort—Saquinavir—acquired immunodeficiency syndrome	6.05e-05	0.000231	CcSEcCtD
Paroxetine—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	6.03e-05	0.00023	CcSEcCtD
Paroxetine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	6.01e-05	0.000229	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	6.01e-05	0.000229	CcSEcCtD
Paroxetine—Shock—Ritonavir—acquired immunodeficiency syndrome	6e-05	0.000229	CcSEcCtD
Paroxetine—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	5.99e-05	0.000228	CcSEcCtD
Paroxetine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	5.99e-05	0.000228	CcSEcCtD
Paroxetine—Cough—Lamivudine—acquired immunodeficiency syndrome	5.99e-05	0.000228	CcSEcCtD
Paroxetine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	5.99e-05	0.000228	CcSEcCtD
Paroxetine—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	5.98e-05	0.000228	CcSEcCtD
Paroxetine—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	5.97e-05	0.000228	CcSEcCtD
Paroxetine—Dizziness—Stavudine—acquired immunodeficiency syndrome	5.97e-05	0.000228	CcSEcCtD
Paroxetine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	5.97e-05	0.000227	CcSEcCtD
Paroxetine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	5.97e-05	0.000227	CcSEcCtD
Paroxetine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	5.95e-05	0.000227	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	5.95e-05	0.000227	CcSEcCtD
Paroxetine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	5.95e-05	0.000227	CcSEcCtD
Paroxetine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	5.94e-05	0.000227	CcSEcCtD
Paroxetine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	5.94e-05	0.000227	CcSEcCtD
Paroxetine—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	5.92e-05	0.000226	CcSEcCtD
Paroxetine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	5.92e-05	0.000226	CcSEcCtD
Paroxetine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	5.92e-05	0.000226	CcSEcCtD
Paroxetine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	5.9e-05	0.000225	CcSEcCtD
Paroxetine—Pain—Efavirenz—acquired immunodeficiency syndrome	5.9e-05	0.000225	CcSEcCtD
Paroxetine—Constipation—Efavirenz—acquired immunodeficiency syndrome	5.9e-05	0.000225	CcSEcCtD
Paroxetine—Rash—Nevirapine—acquired immunodeficiency syndrome	5.89e-05	0.000225	CcSEcCtD
Paroxetine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	5.89e-05	0.000225	CcSEcCtD
Paroxetine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	5.88e-05	0.000224	CcSEcCtD
Paroxetine—Dizziness—Abacavir—acquired immunodeficiency syndrome	5.88e-05	0.000224	CcSEcCtD
Paroxetine—Oedema—Saquinavir—acquired immunodeficiency syndrome	5.87e-05	0.000224	CcSEcCtD
Paroxetine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	5.86e-05	0.000224	CcSEcCtD
Paroxetine—Headache—Nevirapine—acquired immunodeficiency syndrome	5.86e-05	0.000223	CcSEcCtD
Paroxetine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	5.84e-05	0.000223	CcSEcCtD
Paroxetine—Myalgia—Lamivudine—acquired immunodeficiency syndrome	5.84e-05	0.000223	CcSEcCtD
Paroxetine—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	5.84e-05	0.000223	CcSEcCtD
Paroxetine—Infection—Saquinavir—acquired immunodeficiency syndrome	5.83e-05	0.000222	CcSEcCtD
Paroxetine—Anxiety—Lamivudine—acquired immunodeficiency syndrome	5.82e-05	0.000222	CcSEcCtD
Paroxetine—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	5.81e-05	0.000221	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	5.8e-05	0.000221	CcSEcCtD
Paroxetine—Urticaria—Indinavir—acquired immunodeficiency syndrome	5.8e-05	0.000221	CcSEcCtD
Paroxetine—Shock—Saquinavir—acquired immunodeficiency syndrome	5.78e-05	0.00022	CcSEcCtD
Paroxetine—Discomfort—Lamivudine—acquired immunodeficiency syndrome	5.77e-05	0.00022	CcSEcCtD
Paroxetine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	5.77e-05	0.00022	CcSEcCtD
Paroxetine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	5.77e-05	0.00022	CcSEcCtD
Paroxetine—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	5.76e-05	0.000219	CcSEcCtD
Paroxetine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	5.76e-05	0.000219	CcSEcCtD
Paroxetine—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	5.75e-05	0.000219	CcSEcCtD
Paroxetine—Vomiting—Stavudine—acquired immunodeficiency syndrome	5.74e-05	0.000219	CcSEcCtD
Paroxetine—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	5.73e-05	0.000219	CcSEcCtD
Paroxetine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	5.71e-05	0.000218	CcSEcCtD
Paroxetine—Rash—Nelfinavir—acquired immunodeficiency syndrome	5.71e-05	0.000218	CcSEcCtD
Paroxetine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	5.7e-05	0.000217	CcSEcCtD
Paroxetine—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	5.7e-05	0.000217	CcSEcCtD
Paroxetine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	5.7e-05	0.000217	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	5.69e-05	0.000217	CcSEcCtD
Paroxetine—Rash—Stavudine—acquired immunodeficiency syndrome	5.69e-05	0.000217	CcSEcCtD
Paroxetine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	5.69e-05	0.000217	CcSEcCtD
Paroxetine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	5.69e-05	0.000217	CcSEcCtD
Paroxetine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	5.68e-05	0.000217	CcSEcCtD
Paroxetine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	5.68e-05	0.000216	CcSEcCtD
Paroxetine—Headache—Nelfinavir—acquired immunodeficiency syndrome	5.67e-05	0.000216	CcSEcCtD
Paroxetine—Headache—Stavudine—acquired immunodeficiency syndrome	5.65e-05	0.000216	CcSEcCtD
Paroxetine—Vomiting—Abacavir—acquired immunodeficiency syndrome	5.65e-05	0.000216	CcSEcCtD
Paroxetine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	5.65e-05	0.000215	CcSEcCtD
Paroxetine—Pain—Delavirdine—acquired immunodeficiency syndrome	5.64e-05	0.000215	CcSEcCtD
Paroxetine—Constipation—Delavirdine—acquired immunodeficiency syndrome	5.64e-05	0.000215	CcSEcCtD
Paroxetine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	5.64e-05	0.000215	CcSEcCtD
Paroxetine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	5.63e-05	0.000215	CcSEcCtD
Paroxetine—Rash—Abacavir—acquired immunodeficiency syndrome	5.61e-05	0.000214	CcSEcCtD
Paroxetine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	5.6e-05	0.000214	CcSEcCtD
Paroxetine—Oedema—Lamivudine—acquired immunodeficiency syndrome	5.6e-05	0.000214	CcSEcCtD
Paroxetine—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	5.6e-05	0.000214	CcSEcCtD
Paroxetine—Headache—Abacavir—acquired immunodeficiency syndrome	5.57e-05	0.000212	CcSEcCtD
Paroxetine—Infection—Lamivudine—acquired immunodeficiency syndrome	5.56e-05	0.000212	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	5.56e-05	0.000212	CcSEcCtD
Paroxetine—Nausea—Nevirapine—acquired immunodeficiency syndrome	5.55e-05	0.000212	CcSEcCtD
Paroxetine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	5.55e-05	0.000212	CcSEcCtD
Paroxetine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	5.52e-05	0.00021	CcSEcCtD
Paroxetine—Shock—Lamivudine—acquired immunodeficiency syndrome	5.51e-05	0.00021	CcSEcCtD
Paroxetine—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	5.49e-05	0.000209	CcSEcCtD
Paroxetine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	5.49e-05	0.000209	CcSEcCtD
Paroxetine—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	5.48e-05	0.000209	CcSEcCtD
Paroxetine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	5.48e-05	0.000209	CcSEcCtD
Paroxetine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	5.48e-05	0.000209	CcSEcCtD
Paroxetine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	5.45e-05	0.000208	CcSEcCtD
Paroxetine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	5.45e-05	0.000208	CcSEcCtD
Paroxetine—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	5.44e-05	0.000207	CcSEcCtD
Paroxetine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	5.44e-05	0.000207	CcSEcCtD
Paroxetine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	5.44e-05	0.000207	CcSEcCtD
Paroxetine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	5.42e-05	0.000207	CcSEcCtD
Paroxetine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	5.41e-05	0.000206	CcSEcCtD
Paroxetine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	5.39e-05	0.000206	CcSEcCtD
Paroxetine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	5.38e-05	0.000205	CcSEcCtD
Paroxetine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	5.38e-05	0.000205	CcSEcCtD
Paroxetine—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	5.37e-05	0.000205	CcSEcCtD
Paroxetine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	5.37e-05	0.000205	CcSEcCtD
Paroxetine—Nausea—Stavudine—acquired immunodeficiency syndrome	5.36e-05	0.000204	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	5.35e-05	0.000204	CcSEcCtD
Paroxetine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	5.31e-05	0.000202	CcSEcCtD
Paroxetine—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	5.3e-05	0.000202	CcSEcCtD
Paroxetine—Nausea—Abacavir—acquired immunodeficiency syndrome	5.28e-05	0.000201	CcSEcCtD
Paroxetine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	5.27e-05	0.000201	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	5.27e-05	0.000201	CcSEcCtD
Paroxetine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	5.26e-05	0.0002	CcSEcCtD
Paroxetine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	5.24e-05	0.0002	CcSEcCtD
Paroxetine—Asthenia—Indinavir—acquired immunodeficiency syndrome	5.24e-05	0.0002	CcSEcCtD
Paroxetine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	5.23e-05	0.0002	CcSEcCtD
Paroxetine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	5.23e-05	0.0002	CcSEcCtD
Paroxetine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	5.22e-05	0.000199	CcSEcCtD
Paroxetine—Pain—Ritonavir—acquired immunodeficiency syndrome	5.22e-05	0.000199	CcSEcCtD
Paroxetine—Constipation—Ritonavir—acquired immunodeficiency syndrome	5.22e-05	0.000199	CcSEcCtD
Paroxetine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	5.21e-05	0.000199	CcSEcCtD
Paroxetine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	5.21e-05	0.000199	CcSEcCtD
Paroxetine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	5.19e-05	0.000198	CcSEcCtD
Paroxetine—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	5.17e-05	0.000197	CcSEcCtD
Paroxetine—Pruritus—Indinavir—acquired immunodeficiency syndrome	5.16e-05	0.000197	CcSEcCtD
Paroxetine—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	5.1e-05	0.000195	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	5.1e-05	0.000195	CcSEcCtD
Paroxetine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	5.08e-05	0.000194	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	5.07e-05	0.000193	CcSEcCtD
Paroxetine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	5.07e-05	0.000193	CcSEcCtD
Paroxetine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	5.06e-05	0.000193	CcSEcCtD
Paroxetine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	5.03e-05	0.000192	CcSEcCtD
Paroxetine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	5.03e-05	0.000192	CcSEcCtD
Paroxetine—Constipation—Saquinavir—acquired immunodeficiency syndrome	5.02e-05	0.000191	CcSEcCtD
Paroxetine—Pain—Saquinavir—acquired immunodeficiency syndrome	5.02e-05	0.000191	CcSEcCtD
Paroxetine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	4.99e-05	0.00019	CcSEcCtD
Paroxetine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	4.99e-05	0.00019	CcSEcCtD
Paroxetine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	4.99e-05	0.00019	CcSEcCtD
Paroxetine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	4.99e-05	0.00019	CcSEcCtD
Paroxetine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	4.98e-05	0.00019	CcSEcCtD
Paroxetine—Rash—Zidovudine—acquired immunodeficiency syndrome	4.95e-05	0.000189	CcSEcCtD
Paroxetine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	4.95e-05	0.000189	CcSEcCtD
Paroxetine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	4.94e-05	0.000188	CcSEcCtD
Paroxetine—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	4.93e-05	0.000188	CcSEcCtD
Paroxetine—Headache—Zidovudine—acquired immunodeficiency syndrome	4.92e-05	0.000187	CcSEcCtD
Paroxetine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	4.88e-05	0.000186	CcSEcCtD
Paroxetine—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	4.87e-05	0.000186	CcSEcCtD
Paroxetine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	4.86e-05	0.000185	CcSEcCtD
Paroxetine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	4.85e-05	0.000185	CcSEcCtD
Paroxetine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	4.84e-05	0.000184	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	4.84e-05	0.000184	CcSEcCtD
Paroxetine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	4.83e-05	0.000184	CcSEcCtD
Paroxetine—Dizziness—Indinavir—acquired immunodeficiency syndrome	4.82e-05	0.000184	CcSEcCtD
Paroxetine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	4.82e-05	0.000184	CcSEcCtD
Paroxetine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	4.82e-05	0.000184	CcSEcCtD
Paroxetine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	4.8e-05	0.000183	CcSEcCtD
Paroxetine—Pain—Lamivudine—acquired immunodeficiency syndrome	4.79e-05	0.000183	CcSEcCtD
Paroxetine—Constipation—Lamivudine—acquired immunodeficiency syndrome	4.79e-05	0.000183	CcSEcCtD
Paroxetine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	4.73e-05	0.00018	CcSEcCtD
Paroxetine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	4.72e-05	0.00018	CcSEcCtD
Paroxetine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	4.67e-05	0.000178	CcSEcCtD
Paroxetine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	4.66e-05	0.000178	CcSEcCtD
Paroxetine—Nausea—Zidovudine—acquired immunodeficiency syndrome	4.66e-05	0.000178	CcSEcCtD
Paroxetine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	4.64e-05	0.000177	CcSEcCtD
Paroxetine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	4.64e-05	0.000177	CcSEcCtD
Paroxetine—Vomiting—Indinavir—acquired immunodeficiency syndrome	4.64e-05	0.000177	CcSEcCtD
Paroxetine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	4.62e-05	0.000176	CcSEcCtD
Paroxetine—Rash—Indinavir—acquired immunodeficiency syndrome	4.6e-05	0.000175	CcSEcCtD
Paroxetine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	4.6e-05	0.000175	CcSEcCtD
Paroxetine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	4.58e-05	0.000175	CcSEcCtD
Paroxetine—Headache—Indinavir—acquired immunodeficiency syndrome	4.57e-05	0.000174	CcSEcCtD
Paroxetine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	4.56e-05	0.000174	CcSEcCtD
Paroxetine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	4.51e-05	0.000172	CcSEcCtD
Paroxetine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	4.49e-05	0.000171	CcSEcCtD
Paroxetine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	4.45e-05	0.00017	CcSEcCtD
Paroxetine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	4.43e-05	0.000169	CcSEcCtD
Paroxetine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	4.43e-05	0.000169	CcSEcCtD
Paroxetine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	4.38e-05	0.000167	CcSEcCtD
Paroxetine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	4.38e-05	0.000167	CcSEcCtD
Paroxetine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	4.36e-05	0.000166	CcSEcCtD
Paroxetine—Rash—Efavirenz—acquired immunodeficiency syndrome	4.35e-05	0.000166	CcSEcCtD
Paroxetine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	4.34e-05	0.000166	CcSEcCtD
Paroxetine—Nausea—Indinavir—acquired immunodeficiency syndrome	4.33e-05	0.000165	CcSEcCtD
Paroxetine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	4.33e-05	0.000165	CcSEcCtD
Paroxetine—Headache—Efavirenz—acquired immunodeficiency syndrome	4.32e-05	0.000165	CcSEcCtD
Paroxetine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	4.32e-05	0.000165	CcSEcCtD
Paroxetine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	4.21e-05	0.000161	CcSEcCtD
Paroxetine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	4.19e-05	0.00016	CcSEcCtD
Paroxetine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	4.17e-05	0.000159	CcSEcCtD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.17e-05	0.00125	CbGpPWpGaD
Paroxetine—Rash—Delavirdine—acquired immunodeficiency syndrome	4.16e-05	0.000159	CcSEcCtD
Paroxetine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	4.16e-05	0.000158	CcSEcCtD
Paroxetine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	4.15e-05	0.000158	CcSEcCtD
Paroxetine—CHRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.15e-05	0.00125	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.15e-05	0.00125	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.15e-05	0.00125	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.14e-05	0.00124	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.14e-05	0.00124	CbGpPWpGaD
Paroxetine—Headache—Delavirdine—acquired immunodeficiency syndrome	4.13e-05	0.000158	CcSEcCtD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.13e-05	0.00124	CbGpPWpGaD
Paroxetine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	4.13e-05	0.000157	CcSEcCtD
Paroxetine—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	4.11e-05	0.00123	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.1e-05	0.00123	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.1e-05	0.00123	CbGpPWpGaD
Paroxetine—Nausea—Efavirenz—acquired immunodeficiency syndrome	4.09e-05	0.000156	CcSEcCtD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.09e-05	0.00123	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.08e-05	0.00122	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.06e-05	0.00122	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.06e-05	0.00122	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.05e-05	0.00122	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.04e-05	0.00121	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.04e-05	0.00121	CbGpPWpGaD
Paroxetine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	4.03e-05	0.000154	CcSEcCtD
Paroxetine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	4.02e-05	0.000153	CcSEcCtD
Paroxetine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	4.02e-05	0.000153	CcSEcCtD
Paroxetine—CHRM2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4e-05	0.0012	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.97e-05	0.00119	CbGpPWpGaD
Paroxetine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	3.96e-05	0.000151	CcSEcCtD
Paroxetine—CHRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.95e-05	0.00119	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.94e-05	0.00118	CbGpPWpGaD
Paroxetine—SLC6A3—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.93e-05	0.00118	CbGpPWpGaD
Paroxetine—Nausea—Delavirdine—acquired immunodeficiency syndrome	3.92e-05	0.000149	CcSEcCtD
Paroxetine—CHRM2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.9e-05	0.00117	CbGpPWpGaD
Paroxetine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	3.88e-05	0.000148	CcSEcCtD
Paroxetine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	3.88e-05	0.000148	CcSEcCtD
Paroxetine—Rash—Ritonavir—acquired immunodeficiency syndrome	3.85e-05	0.000147	CcSEcCtD
Paroxetine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	3.84e-05	0.000146	CcSEcCtD
Paroxetine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	3.83e-05	0.000146	CcSEcCtD
Paroxetine—Headache—Ritonavir—acquired immunodeficiency syndrome	3.82e-05	0.000146	CcSEcCtD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.75e-05	0.00113	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.73e-05	0.00112	CbGpPWpGaD
Paroxetine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	3.73e-05	0.000142	CcSEcCtD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.72e-05	0.00112	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.71e-05	0.00112	CbGpPWpGaD
Paroxetine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	3.7e-05	0.000141	CcSEcCtD
Paroxetine—Rash—Saquinavir—acquired immunodeficiency syndrome	3.7e-05	0.000141	CcSEcCtD
Paroxetine—CHRM4—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.7e-05	0.00111	CbGpPWpGaD
Paroxetine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	3.7e-05	0.000141	CcSEcCtD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	3.7e-05	0.00111	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.69e-05	0.00111	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.69e-05	0.00111	CbGpPWpGaD
Paroxetine—Headache—Saquinavir—acquired immunodeficiency syndrome	3.68e-05	0.00014	CcSEcCtD
Paroxetine—CHRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.67e-05	0.0011	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.65e-05	0.0011	CbGpPWpGaD
Paroxetine—Nausea—Ritonavir—acquired immunodeficiency syndrome	3.62e-05	0.000138	CcSEcCtD
Paroxetine—CHRM2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.62e-05	0.00109	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—TAT—acquired immunodeficiency syndrome	3.61e-05	0.00109	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AGPS—acquired immunodeficiency syndrome	3.57e-05	0.00107	CbGpPWpGaD
Paroxetine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	3.56e-05	0.000136	CcSEcCtD
Paroxetine—CHRM5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.56e-05	0.00107	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.55e-05	0.00107	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.55e-05	0.00107	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.54e-05	0.00106	CbGpPWpGaD
Paroxetine—Rash—Lamivudine—acquired immunodeficiency syndrome	3.53e-05	0.000135	CcSEcCtD
Paroxetine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	3.53e-05	0.000135	CcSEcCtD
Paroxetine—Headache—Lamivudine—acquired immunodeficiency syndrome	3.51e-05	0.000134	CcSEcCtD
Paroxetine—Nausea—Saquinavir—acquired immunodeficiency syndrome	3.49e-05	0.000133	CcSEcCtD
Paroxetine—CHRM4—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.48e-05	0.00104	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.48e-05	0.00104	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.4e-05	0.00102	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.4e-05	0.00102	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.36e-05	0.00101	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.33e-05	0.001	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.33e-05	0.001	CbGpPWpGaD
Paroxetine—Nausea—Lamivudine—acquired immunodeficiency syndrome	3.33e-05	0.000127	CcSEcCtD
Paroxetine—CHRM5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.22e-05	0.000966	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.21e-05	0.000965	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.17e-05	0.000953	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.16e-05	0.000949	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.16e-05	0.000949	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.16e-05	0.000948	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.15e-05	0.000945	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.12e-05	0.000936	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.09e-05	0.000928	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.08e-05	0.000924	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AGPS—acquired immunodeficiency syndrome	3.07e-05	0.000923	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	3.06e-05	0.000919	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.04e-05	0.000914	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.02e-05	0.000908	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.02e-05	0.000908	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	3.02e-05	0.000907	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3e-05	0.000901	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	2.99e-05	0.000898	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.86e-05	0.000859	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.84e-05	0.000854	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.83e-05	0.000851	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.81e-05	0.000843	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.78e-05	0.000836	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	2.76e-05	0.000828	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.72e-05	0.000818	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	2.71e-05	0.000813	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	2.66e-05	0.0008	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.65e-05	0.000795	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.61e-05	0.000783	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	2.6e-05	0.000781	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.53e-05	0.000761	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.52e-05	0.000756	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	2.51e-05	0.000754	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.51e-05	0.000753	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.5e-05	0.000752	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.5e-05	0.00075	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.5e-05	0.00075	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.49e-05	0.000749	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	2.49e-05	0.000748	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.49e-05	0.000747	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.47e-05	0.000743	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.46e-05	0.000739	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.43e-05	0.000731	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.41e-05	0.000723	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.41e-05	0.000723	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.4e-05	0.000722	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.39e-05	0.000719	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.39e-05	0.000719	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.39e-05	0.000717	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.39e-05	0.000717	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.38e-05	0.000716	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.37e-05	0.000711	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.36e-05	0.00071	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.36e-05	0.00071	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.36e-05	0.000708	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.36e-05	0.000708	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.34e-05	0.000704	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.34e-05	0.000704	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.34e-05	0.000702	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.34e-05	0.000702	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.31e-05	0.000695	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.31e-05	0.000695	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.3e-05	0.000691	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.28e-05	0.000686	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.28e-05	0.000684	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.27e-05	0.000681	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.27e-05	0.000681	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.26e-05	0.00068	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.26e-05	0.000678	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.25e-05	0.000677	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.24e-05	0.000671	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.23e-05	0.000669	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.19e-05	0.000659	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.19e-05	0.000656	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.18e-05	0.000654	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.17e-05	0.00065	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.16e-05	0.00065	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.16e-05	0.000648	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.14e-05	0.000643	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.14e-05	0.000643	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.14e-05	0.000642	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	2.14e-05	0.000641	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.13e-05	0.00064	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.13e-05	0.00064	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.12e-05	0.000638	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.12e-05	0.000638	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	2.12e-05	0.000636	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.1e-05	0.000631	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.1e-05	0.000631	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.1e-05	0.000631	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.07e-05	0.000623	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2e-05	0.000599	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.98e-05	0.000596	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.9e-05	0.000571	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.87e-05	0.00056	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.87e-05	0.00056	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.81e-05	0.000543	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.79e-05	0.000539	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.79e-05	0.000537	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.79e-05	0.000537	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.78e-05	0.000536	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.78e-05	0.000534	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.77e-05	0.000531	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.76e-05	0.000529	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.76e-05	0.000528	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.75e-05	0.000526	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.73e-05	0.000521	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.72e-05	0.000517	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.71e-05	0.000514	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.71e-05	0.000513	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.63e-05	0.000489	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.62e-05	0.000487	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.62e-05	0.000485	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.61e-05	0.000485	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.61e-05	0.000483	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.61e-05	0.000483	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.6e-05	0.000482	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.6e-05	0.000481	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.6e-05	0.000481	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.6e-05	0.00048	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.6e-05	0.000479	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.59e-05	0.000478	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.59e-05	0.000476	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.58e-05	0.000473	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.49e-05	0.000447	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.48e-05	0.000444	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.48e-05	0.000443	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.47e-05	0.000443	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.47e-05	0.000441	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.46e-05	0.000439	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.46e-05	0.000438	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.45e-05	0.000437	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.44e-05	0.000433	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.42e-05	0.000426	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.4e-05	0.00042	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.38e-05	0.000414	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.36e-05	0.000408	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.35e-05	0.000404	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.34e-05	0.000402	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.34e-05	0.000402	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.33e-05	0.000401	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.32e-05	0.000397	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.32e-05	0.000396	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.28e-05	0.000384	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.26e-05	0.00038	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.26e-05	0.00038	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.26e-05	0.000378	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.26e-05	0.000378	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.25e-05	0.000377	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.25e-05	0.000377	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.25e-05	0.000376	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.24e-05	0.000373	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.24e-05	0.000373	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.22e-05	0.000368	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.2e-05	0.00036	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.2e-05	0.00036	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.92e-06	0.000298	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	9.75e-06	0.000293	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.62e-06	0.000289	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.57e-06	0.000287	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.54e-06	0.000287	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.48e-06	0.000285	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.46e-06	0.000284	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.45e-06	0.000284	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.43e-06	0.000283	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.4e-06	0.000282	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.34e-06	0.00028	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.31e-06	0.000279	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.29e-06	0.000279	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.26e-06	0.000278	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.17e-06	0.000275	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.67e-06	0.00026	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.62e-06	0.000259	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.59e-06	0.000258	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.51e-06	0.000256	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.48e-06	0.000255	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.43e-06	0.000253	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.41e-06	0.000252	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.32e-06	0.00025	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.39e-06	0.000222	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.35e-06	0.000221	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	7.32e-06	0.00022	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.07e-06	0.000212	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.04e-06	0.000211	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	6.3e-06	0.000189	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	5.33e-06	0.00016	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.01e-06	0.00015	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.98e-06	0.00015	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.98e-06	0.00015	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.97e-06	0.000149	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.96e-06	0.000149	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.94e-06	0.000148	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.92e-06	0.000148	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.89e-06	0.000147	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	4.65e-06	0.00014	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	4.38e-06	0.000132	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.34e-06	0.00013	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	4.34e-06	0.00013	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.16e-06	0.000125	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.94e-06	8.84e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.93e-06	8.79e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.92e-06	8.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.89e-06	8.68e-05	CbGpPWpGaD
